EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Preservative-free Unit-Dose Sodium Hyaluronate Eye Drops (0.3%) Obtained Approval from NMPA for Commercialisation in China

2024.09.13

Essex Bio-Technology Reports 1st H 2024 Net Profit of HK$157.4 Million Poised for Future Success Underpinned by Proven Product Base and Promising Pipeline of Products

2024.08.26

Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2024

2024.08.26

Date

Title

2024-09-13

Preservative-free Unit-Dose Sodium Hyaluronate Eye Drops (0.3%) Obtained Approval from NMPA for Commercialisation in China

2024-08-26

Essex Bio-Technology (1061.HK) 2024 Interim Results at a glance

2024-08-26

Essex Bio-Technology Reports 1st H 2024 Net Profit of HK$157.4 Million Poised for Future Success Underpinned by Proven Product Base and Promising Pipeline of Products

2024-08-26

Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2024

2024-08-14

Preservative-free Unit-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China

2024-06-27

EssexBio has climbed 13 places over the previous year in “China Pharmaceutical Industry Top 100 Series List” & Beifushu® awarded “China Pharmaceutical Brands List” for the sixth consecutive year

2024-03-19

Essex Bio-Technology (1061.HK) 2023 Annual Results at a glance

2024-03-18

Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT